BioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate

  • BioLineRx Ltd BLRX announced results from the Phase 1/2a study of the intratumoral cancer vaccine candidate AGI-134 in patients with unresectable metastatic solid tumors.
  • The study met its primary endpoint of AGI-134's safety and tolerability. 
  • In this first-in-human trial, 38 patients were treated with AGI-134. 
  • Part 1 demonstrated that AGI-134 was safe and well tolerated, with no dose-limiting toxicities reported. 
  • The maximum tolerated dose was not reached, and the recommended dose for part 2 of the study (RP2D) was determined to be up to 200mg. 
  • In the dose expansion part 2 of the study, AGI-134 was generally well-tolerated, with treatment-related adverse events being transient and primarily mild to moderate.
  • Most patients analyzed showed an increase in Alpha-Gal antibodies, indicating increased overall immune activity. 
  • Additionally, increases in antigen-presenting cells (APCs) were observed in most tissue samples analyzed. 
  • T cell and macrophage tumor infiltration was seen in approximately one-third of evaluable patients' injected tumors and approximately half of evaluable patients' un-injected lesions. 
  • Radiological assessments found that 29% of patients in the trial achieved the best overall response of the stable disease. Seven of the 11 patients who achieved stable disease had previously failed checkpoint-inhibitor therapy. 
  • Price Action: BLRX shares are down 8.90% at $0.56 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!